Login to Your Account

BioCryst Stock Takes a Hit as Peramivir Trial Extended

By Catherine Shaffer

Friday, January 14, 2011
Stock in BioCryst Pharmaceuticals Inc. fell 6.7 percent Thursday after the Research Triangle Park, N.C.-based company said it would extend the enrollment period for a trial of peramivir for hospitalized influenza patients. The company revised its clinical trial design for the study in response to feedback from the Biomedical Advanced Research and Development Authority (BARDA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription